{"disease":{"id":"gram-positive-bacterial-infections","name":"gram positive bacterial infections"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06592586","title":"A Follow-up Trial of GBS-NN/NN2 Vaccine in Healthy Pregnant Women","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":338,"lead_sponsor_name":"Minervax ApS","has_results":false},{"nct_id":"NCT03159403","title":"A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting","phase":"","overall_status":"COMPLETED","enrollment_count":325,"lead_sponsor_name":"Melinta Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03896685","title":"Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":323,"lead_sponsor_name":"Médecins Sans Frontières, France","has_results":false},{"nct_id":"NCT04917380","title":"The Clinical Character，Risk and Prognosis of Post-neurosurgical Intracranial Infection With Different Pathogens.","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT03438214","title":"Effect of Intermittent Infusion Versus Continuous Infusion of Vancomycin on Kidney Failure in Critically Ill Patients","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":222,"lead_sponsor_name":"University of Sao Paulo","has_results":false},{"nct_id":"NCT03747497","title":"Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":196,"lead_sponsor_name":"MicuRx","has_results":true},{"nct_id":"NCT03964493","title":"TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"TenNor Therapeutics Limited","has_results":true},{"nct_id":"NCT00055198","title":"Daptomycin for the Treatment of Infections Due to Gram-Positive Bacteria","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":75,"lead_sponsor_name":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":false},{"nct_id":"NCT04911270","title":"Clinical Decision Support Tool for Vancomycin Dosing in Children","phase":"NA","overall_status":"COMPLETED","enrollment_count":75,"lead_sponsor_name":"University of Maryland, Baltimore","has_results":false},{"nct_id":"NCT00136292","title":"Study of Single Dose Daptomycin in Pediatric Patients With Gram-positive Infection for Which They Are Receiving Standard Antibiotics","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":false},{"nct_id":"NCT02750761","title":"A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT06444802","title":"Model-informed Precision Dosing for Linezolid","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":28,"lead_sponsor_name":"University of Hamburg-Eppendorf","has_results":false},{"nct_id":"NCT03361163","title":"Controlled Human Infection for Vaccination Against Streptococcus Pyogenes","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Andrew Steer","has_results":false},{"nct_id":"NCT04847921","title":"Substance Use Disorder (SUD)-Associated Infections' Treatment With Dalbavancin ENabling OUtpatient Transition","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"University of Colorado, Denver","has_results":false}],"total":14},"guidelines":[],"source":"Drug Landscape verified database"}